Potential diagnostic biomarkers for schizophrenia-Reference-Cited by-全球学者库

Potential diagnostic biomarkers for schizophrenia

Published:2022-08-01 Issue:4 Volume:2 Page:385-416
ISSN:2749-9642
Container-title:Medical Review
language:en
Short-container-title:

Author:

Yue Weihua¹²³⁴^ORCID,Huang Hailiang⁵⁶⁷,Duan Jubao⁸⁹

Affiliation:

1. Institute of Mental Health, Peking University Sixth Hospital , Beijing , China

2. National Clinical Research Center for Mental Disorders & NHC Key Laboratory of Mental Health (Peking University) and Chinese Academy of Medical Sciences Research Unit , Beijing , China

3. PKU-IDG/McGovern Institute for Brain Research, Peking University , Beijing , China

4. Chinese Institute for Brain Research , Beijing , China

5. Analytic and Translational Genetics Unit, Massachusetts General Hospital , Boston , MA , USA

6. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard , Cambridge , MA , USA

7. Department of Medicine , Harvard Medical School , Boston , MA , USA

8. Center for Psychiatric Genetics, NorthShore University Health System , Evanston , IL , USA

9. Department of Psychiatry and Behavioral Neurosciences , University of Chicago , Chicago , IL , USA

Abstract

Abstract Schizophrenia (SCH) is a complex and severe mental disorder with high prevalence, disability, mortality and carries a heavy disease burden, the lifetime prevalence of SCH is around 0.7%–1.0%, which has a profound impact on the individual and society. In the clinical practice of SCH, key problems such as subjective diagnosis, experiential treatment, and poor overall prognosis are still challenging. In recent years, some exciting discoveries have been made in the research on objective biomarkers of SCH, mainly focusing on genetic susceptibility genes, metabolic indicators, immune indices, brain imaging, electrophysiological characteristics. This review aims to summarize the biomarkers that may be used for the prediction and diagnosis of SCH.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/mr-2022-0009/pdf

Reference252 articles.

1. Owen, MJ, Sawa, A, Mortensen, PB. Schizophrenia. Lancet 2016;388:86–97. https://doi.org/10.1016/s0140-6736(15)01121-6.

2. Brody, H. Schizophrenia. Nature 2014;508:S1. https://doi.org/10.1038/508s1a.

3. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211–59.

4. Huang, Y, Wang, Y, Wang, H, Liu, Z, Yu, X, Yan, J, et al.. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatr 2019;6:211–24. https://doi.org/10.1016/s2215-0366(18)30511-x.

5. Kooyman, I, Dean, K, Harvey, S, Walsh, E. Outcomes of public concern in schizophrenia. Br J Psychiatr Suppl 2007;50:s29–36. https://doi.org/10.1192/bjp.191.50.s29.